Likarda

Many life-saving treatments are being held up by the same hurdles. Cell therapies require a unique mix of cell delivery, controlled release, and optimized microenvironments to be effective. Likarda has designed groundbreaking delivery systems that take these factors into account, and that can be optimized to your specific therapy's needs to ensure maximum effectiveness. 🔬 One such delivery system is the VitaCell™, which has features such as: - Ensured Cell Retention - Controlled Release - Enhanced Viability - Regulatory Ease Learn more about VitaCell™ and our other delivery solutions at Likarda.com. #Biotech #CellTherapy #HealthcareTechnology #CellTherapySolutions

Transform your cell therapy or biologic with Likarda’s cutting-edge encapsulation technology. Our hydrogels and microbeads are designed to optimize delivery, ensuring your therapeutics achieve maximum impact. Why Choose Likarda? 50+ Hydrogel Formulations: Tailored to meet the specific needs of your therapy. 45+ Patents: Protecting innovative solutions in cell and molecule delivery. 40+ Cell Types: Expertise across a diverse range of cells. 📥 Read our free brochure to explore how our hydrogels could optimize your therapy and join us in revolutionizing healthcare. Download Here: https://lnkd.in/gaKqpQEN #CellTherapy #HydrogelTechnology #HealthcareInnovation

Cell therapies represent a frontier in battling diseases once deemed "untreatable." Precise delivery is crucial for these new therapies to succeed, but ensuring they remain at their target sites to unleash their full potential is challenging. At Likarda, we don't shy away from those challenges—we solve them. That's why we have developed customizable encapsulation technology, unique in its ability to precisely cater to the delivery and release requirements of your cell therapy or molecule. As shown in the chart, for each hurdle, we have a solution. For example: - Retention at Target Site: VitaCell™ ensures cells stay where they're needed. - Immune Rejection: EnduraCell™ offers long-term protection from immune rejection. - Freezing Issues: VitaCell™ and LiberaCell™ protect cells during freeze/thaw, ensuring easier shipping. Whether it's sustaining release over extended periods or targeting immediate impact, our technology maximizes the clinical impact of your cell therapies and molecules. Discover how our solutions can help your therapies reach their full potential at Likarda.com #BiotechStartup #HealthcareInnovation #CellTherapy #ImmuneTherapy

How can we help companies get more patients and physician access to new treatment options? "A key focus should be reducing dosing for most cell therapies. More targeted delivery to specific locations can cut costs and minimise off-target toxicity." Stella K. Vnook.'' Contact us to explore how your product plan can take shape. https://lnkd.in/eSbjeHcy

Curious about the services Likarda offers? In this brief video, you'll get a peak into feasibility studies and see how our Core Shell Spherification™ (CSS) technology uses customized hydrogels to meet your project needs. Watch now to discover our cutting-edge technologies and see how we're pioneering the future of cell therapy delivery. How can we help you? www.likarda.com #Biotech #CellDelivery #CellTherapy

An amazing interview with our CEO, Dr. Stella Vnook. Please take a few minutes to listen to her inspiring story.

Ever wondered what it takes to turn groundbreaking ideas into reality? The Medicine Maker sat down with Stella K. Vnook, Likarda's inspiring CEO, to learn about her incredible journey from a pharmacy school intern to leading a biotech company looking to revolutionize cell therapy for diabetes and other illnesses.   Read on to learn more about: • How Stella's passion for expanding drug options led her into the world of drug discovery and commercialization.   • The unique benefits of Likarda's Core Shell Spherification technology in optimizing Biologics and Cell Therapies.   • The importance of drug delivery in advancing healthcare and insights into the regulatory landscape.   • Stella’s personal story of resilience and determination, from her early days in Belarus to her drive to succeed in the US.   Big thanks to The Medicine Maker for this compelling read that gives a glimpse into the innovation, leadership, and spirit of Dr. Vnook and Likarda. You can read the full interview here: https://bit.ly/3VRPGMw #femaleceo #womeninbusiness #womeninstem #biotech

At Likarda, we’re revolutionizing the future of cell therapy delivery with our patented Core-Shell Spherification® (CSS) technology. CSS encapsulates biological therapies like cells, peptides, and antibodies in a hydrogel that is crosslinked forming stable, injectable microbeads. This breakthrough allows precise control over factors, such as microbead size and release rates, ensuring targeted delivery and sustained therapeutic impact. Our extensive library of over 50 hydrogel formulations is tailored for various therapeutic applications. For instance, durable hydrogels are ideal for maintaining transplanted cells in place for long-term treatments, like delivering insulin-producing cells for diabetes. In contrast, degradable hydrogels allow controlled release, perfect for therapies requiring interaction with surrounding tissues, such as stem cells for osteoarthritis. This flexibility ensures that each therapy achieves its maximum potential, setting a new standard in the biotech industry. We've developed a brochure that gives more information on our hydrogels and how they're able to overcome existing challenges. Learn More: https://lnkd.in/gaKqpQEN #biotech #healthcareinnovation #celltherapy #hydrogels

Don’t Miss Likarda’s Presentation at the Global Cell & Gene Therapy Summit! We’re just a day away from a transformative presentation by Likarda's CEO, Dr. Stella K. Vnook. Join us to uncover the future of cell therapy! 📅 Date: Tuesday, July 9 🕓 Time: 4:00 PM 📍 Location: The Global Cell and Gene Therapy Summit: https://cgtsummit.com #CellTherapy #GeneTherapy #Biotech #Cryopreservation #HealthcareInnovation

In Case You Missed It | Our recent #LikardaKonnect webinar was a productive discussion on optimizing approaches to making Cell Therapies for Diabetes a Reality. If you couldn't join us live, don't worry—you can still catch all the valuable insights by watching the recording! Big thanks to Likarda Founder & President, Lisa Stehno-Bittel, who led the conversation with industry experts Dr Jeffrey Millman from Washington University School of Medicine in St. Louis and Sernova CBO, Dr. Modestus Obochi, PhD MBA. Some points touched on were: 💠 Advancements in Clinical Trials: Learn about the latest updates on clinical trials paving the way for new Type 1 diabetes treatments. 💠 iPSc Cells in Product Development: Discover the potential and challenges of using pluripotent cells to create effective therapies. 💠 Regulatory Landscapes: Gain insights into the regulatory environment in the US and Canada and understand what it means for product approval and market entry. 💠 Support Systems for Innovation: Explore the global initiatives and resources driving advancements in diabetes care, especially in cell therapy. This webinar is a must-watch for anyone interested in the forefront of biotech and diabetes treatment. Watch the webinar for free here: https://lnkd.in/gsBmyqgR #celltherapy #diabetes #diabetestreatment #diabetescare